Do analysts rate NTRB or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NTRB or MENS?

Jyong Biotech has lower revenue, but higher earnings than Nutriband. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 27.84 -$8.23M -$2.58 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Do analysts recommend NTRB or LENZ?

LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 515.38%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is NTRB or LENZ more profitable?

Nutriband has a net margin of -448.25% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -448.25% -112.64% -97.86% LENZ Therapeutics -586.74% -53.39% -49.14%

Do analysts rate AARD or NTRB?

Aardvark Therapeutics presently has a consensus price target of $16.30, suggesting a potential upside of 139.00%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.46 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend NTRB or MIST?

Milestone Pharmaceuticals has a consensus target price of $6.40, suggesting a potential upside of 506.64%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Nutriband (NTRB) Competitors

$4.67 0.00 (0.00%)

As of 08/21/2026 03:59 PM Eastern

Compare

NTRB vs. UNCY, MENS, LENZ, AARD, and MIST

Should you buy Nutriband stock or one of its competitors? Nutriband's main competitors and comparable companies include Unicycive Therapeutics (UNCY), Jyong Biotech (MENS), LENZ Therapeutics (LENZ), Aardvark Therapeutics (AARD), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nutriband compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Unicycive Therapeutics has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Unicycive Therapeutics' return on equity of -91.50% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Nutriband	-448.25%	-112.64%	-97.86%

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Nutriband. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 0 mentions for Nutriband. Unicycive Therapeutics' average media sentiment score of 0.76 beat Nutriband's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Positive
Nutriband	Neutral

Nutriband has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A
Nutriband	$2.04M	27.84	-$8.23M	-$2.58	N/A

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Unicycive Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 233.04%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Unicycive Therapeutics beats Nutriband on 11 of the 16 factors compared between the two stocks.

How does Nutriband compare to Jyong Biotech?

Nutriband (NASDAQ:NTRB) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Nutriband has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

19.7% of Nutriband shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Jyong Biotech's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Jyong Biotech	N/A	N/A	N/A

Jyong Biotech has lower revenue, but higher earnings than Nutriband.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	27.84	-$8.23M	-$2.58	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

In the previous week, Nutriband's average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.

Company	Overall Sentiment
Nutriband	Neutral
Jyong Biotech	Neutral

Summary

Jyong Biotech beats Nutriband on 5 of the 9 factors compared between the two stocks.

How does Nutriband compare to LENZ Therapeutics?

Nutriband (NASDAQ:NTRB) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

19.7% of Nutriband shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 515.38%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nutriband has a net margin of -448.25% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Nutriband has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, LENZ Therapeutics had 2 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for Nutriband. LENZ Therapeutics' average media sentiment score of 0.51 beat Nutriband's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nutriband	Neutral
LENZ Therapeutics	Positive

Nutriband has higher earnings, but lower revenue than LENZ Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	27.84	-$8.23M	-$2.58	N/A
LENZ Therapeutics	$19.09M	7.70	-$82.13M	-$4.09	N/A

Summary

LENZ Therapeutics beats Nutriband on 10 of the 16 factors compared between the two stocks.

How does Nutriband compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Aardvark Therapeutics has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Aardvark Therapeutics' return on equity of -71.54% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Nutriband	-448.25%	-112.64%	-97.86%

Aardvark Therapeutics has a beta of 3.8, suggesting that its stock price is 280% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 26 more articles in the media than Nutriband. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 0 mentions for Nutriband. Aardvark Therapeutics' average media sentiment score of 0.05 beat Nutriband's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Nutriband	Neutral

19.7% of Nutriband shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nutriband has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Nutriband	$2.04M	27.84	-$8.23M	-$2.58	N/A

Aardvark Therapeutics presently has a consensus price target of $16.30, suggesting a potential upside of 139.00%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Aardvark Therapeutics beats Nutriband on 10 of the 16 factors compared between the two stocks.

How does Nutriband compare to Milestone Pharmaceuticals?

Nutriband (NASDAQ:NTRB) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Nutriband has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Nutriband has higher revenue and earnings than Milestone Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	27.84	-$8.23M	-$2.58	N/A
Milestone Pharmaceuticals	$1.55M	84.74	-$63.06M	-$0.69	N/A

Milestone Pharmaceuticals has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

In the previous week, Milestone Pharmaceuticals had 8 more articles in the media than Nutriband. MarketBeat recorded 8 mentions for Milestone Pharmaceuticals and 0 mentions for Nutriband. Milestone Pharmaceuticals' average media sentiment score of 0.18 beat Nutriband's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Nutriband	Neutral
Milestone Pharmaceuticals	Neutral

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Milestone Pharmaceuticals has a consensus target price of $6.40, suggesting a potential upside of 506.64%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Milestone Pharmaceuticals beats Nutriband on 12 of the 17 factors compared between the two stocks.

Get Nutriband News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRB vs. The Competition

Export

Metric	Nutriband	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$56.79M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-1.81	789.80	272.91	24.33
Price / Sales	27.84	795.45	639.20	97.25
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	8.49	10.52	11.38	6.42
Net Income	-$8.23M	$2.81B	$3.47B	$348.89M
7 Day Performance	44.58%	2.49%	2.16%	0.51%
1 Month Performance	56.71%	5.06%	7.59%	4.84%
1 Year Performance	-27.37%	7.26%	25.16%	17.04%

Nutriband Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRB Nutriband	0.1118 of 5 stars	$4.67 flat	N/A	-27.4%	$56.79M	$2.04M	N/A	10	Gap Down High Trading Volume
UNCY Unicycive Therapeutics	3.234 of 5 stars	$5.63 +1.1%	$18.25 +224.2%	+34.0%	$155.15M	N/A	N/A	9
MENS Jyong Biotech	N/A	$2.02 +0.5%	N/A	-95.3%	$153.58M	N/A	N/A	31
LENZ LENZ Therapeutics	3.1862 of 5 stars	$4.77 -0.4%	$28.80 +503.8%	-88.3%	$150.50M	$21.48M	N/A	110
AARD Aardvark Therapeutics	2.3573 of 5 stars	$6.14 -8.9%	$16.30 +165.5%	-30.2%	$143.12M	N/A	N/A	18	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRB) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutriband (NTRB) Competitors

NTRB vs. UNCY, MENS, LENZ, AARD, and MIST

How does Nutriband compare to Unicycive Therapeutics?

Summary

How does Nutriband compare to Jyong Biotech?

Summary

How does Nutriband compare to LENZ Therapeutics?

Summary

How does Nutriband compare to Aardvark Therapeutics?

Summary

How does Nutriband compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutriband (NTRB) Competitors

NTRB vs. UNCY, MENS, LENZ, AARD, and MIST

How does Nutriband compare to Unicycive Therapeutics?

Which has more risk and volatility, UNCY or NTRB?

Is UNCY or NTRB more profitable?

Does the media prefer UNCY or NTRB?

Which has better earnings & valuation, UNCY or NTRB?

Do insiders and institutionals have more ownership in UNCY or NTRB?

Do analysts recommend UNCY or NTRB?

Summary

How does Nutriband compare to Jyong Biotech?

Which has more volatility & risk, NTRB or MENS?

Do insiders & institutionals have more ownership in NTRB or MENS?

Do analysts rate NTRB or MENS?

Is NTRB or MENS more profitable?

Which has better earnings and valuation, NTRB or MENS?

Does the media prefer NTRB or MENS?

Summary

How does Nutriband compare to LENZ Therapeutics?

Do insiders and institutionals hold more shares of NTRB or LENZ?

Do analysts recommend NTRB or LENZ?

Is NTRB or LENZ more profitable?

Which has more risk and volatility, NTRB or LENZ?

Does the media refer more to NTRB or LENZ?

Which has higher earnings & valuation, NTRB or LENZ?

Summary

How does Nutriband compare to Aardvark Therapeutics?

Is AARD or NTRB more profitable?

Which has more volatility and risk, AARD or NTRB?

Does the media favor AARD or NTRB?

Do insiders and institutionals have more ownership in AARD or NTRB?

Which has better valuation and earnings, AARD or NTRB?

Do analysts rate AARD or NTRB?

Summary

How does Nutriband compare to Milestone Pharmaceuticals?

Which has more volatility & risk, NTRB or MIST?

Which has better earnings and valuation, NTRB or MIST?

Is NTRB or MIST more profitable?

Does the media prefer NTRB or MIST?

Do institutionals and insiders hold more shares of NTRB or MIST?

Do analysts recommend NTRB or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools